Literature DB >> 28982661

FDA Approves First Biosimilar to Treat Cancer.

.   

Abstract

The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma. A biosimilar to bevacizumab, the agent is the first such drug approved for the treatment of cancer. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28982661     DOI： 10.1158/2159-8290.CD-NB2017-139

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

1.  Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Authors:  Jun Huang; Ciarán P Kelly; Kyriaki Bakirtzi; Javier A Villafuerte Gálvez; Dena Lyras; Steven J Mileto; Sarah Larcombe; Hua Xu; Xiaotong Yang; Kelsey S Shields; Weishu Zhu; Yi Zhang; Jeffrey D Goldsmith; Ishan J Patel; Joshua Hansen; Meijin Huang; Seppo Yla-Herttuala; Alan C Moss; Daniel Paredes-Sabja; Charalabos Pothoulakis; Yatrik M Shah; Jianping Wang; Xinhua Chen
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

2.  Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Xian Xiao; Guixing Zhang; Binxu Sun; Chaoran Wang; Xiaoqun Wang; Fanming Kong; Yingjie Jia
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

Review 3.  Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.

Authors:  Maria Georganaki; Luuk van Hooren; Anna Dimberg
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.